Avenzo Therapeutics, Inc.
Clinical trials sponsored by Avenzo Therapeutics, Inc., explained in plain language.
-
New pill AVZO-023 takes on advanced cancers in first human trial
Disease control Recruiting nowThis study is the first to test AVZO-023, an oral drug that blocks a protein called CDK4, in people with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if it can shrink tumors. About 380 adults with HR+/HER2- brea…
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 04:52 UTC
-
New drug AVZO-1418 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 480 adults will take part in this first human trial.
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 04:50 UTC
-
New drug AVZO-103 targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis study tests a new drug called AVZO-103 in people with advanced bladder cancer or other solid tumors that have spread. The drug is designed to attack cancer cells directly. The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 355 adults …
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 04:35 UTC
-
New pill shows promise against Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new oral drug, AVZO-021, in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called CDK2 to slow or stop cancer growth. The trial has two phases: first to find the safest dose, then to see if it shrinks t…
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC